TGFBR1 and non-small cell lung carcinoma: In NSCLC, YBX1 is recruited by RBMPs to the TGFBR1 promoter [146], activating the TGFBR1/SMAD2/3 pathway, thereby sustaining stemness and EMT characteristics, and ultimately inducing radio resistance and cisplatin resistance.